TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04711239

Intervention type: DIAGNOSTIC_TEST
Intervention: PGT-A / niPGT-A
Description: PGT-A and niPGT-A will be performed using next generation sequencing (NGS) analysis for chromosome copy number variation (CNV). Embryo transfers will rely solely on the results of PGT-A for trophectoderm biopsies.
Study: NCT05913492

Intervention type: BEHAVIORAL
Intervention: Simulation training
Description: Each volunteer went through two simulation scenarios of difficult airway management: 1) cannot intubate, can ventilate (CI), 2) cannot intubate, cannot ventilate (CICV) with the assistance of the training centre operator. Following the first simulation round, volunteers were trained on the same day in difficult airway management according to DAS guidelines, using the same equipment as during the simulation. The participants repeated the simulation scenarios immediately after the training and six months later.

Intervention type: BEHAVIORAL
Intervention: Simulation training
Description: Each volunteer went through two simulation scenarios of difficult airway management: 1) cannot intubate, can ventilate (CI), 2) cannot intubate, cannot ventilate (CICV) with the assistance of the training centre operator. Following the first simulation round, volunteers were trained on the same day in difficult airway management according to DAS guidelines, using the same equipment as during the simulation. The participants repeated the simulation scenarios immediately after the training and six months later.
Study: NCT05963594

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oligomalt
Description: The investigational product (Oligomalt) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oligomalt
Description: The investigational product (Oligomalt) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oligomalt
Description: The investigational product (Oligomalt) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.
Study: NCT06275828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: slow beat mesic listening by headphone
Description: classic slow beat type from researcher
Study: NCT05002933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/ml
Description: Solution for injection Subcutaneous injection
Study: NCT04728906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart patch seeded with autologous cardiomyocytes and amnion epithelial stem cells
Description: heart patch is seeded with patient's cardiomyocytes (taken from patient's heart waste tissue when undergoing bypass surgery) and stock amnion epithelial stem cells (HLA-DR negative to eliminate risk of rejection)
Study: NCT05963594

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oligomalt
Description: The investigational product (Oligomalt) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oligomalt
Description: The investigational product (Oligomalt) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oligomalt
Description: The investigational product (Oligomalt) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: maltodextrin
Description: The investigational product (maltodextrin) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: maltodextrin
Description: The investigational product (maltodextrin) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: maltodextrin
Description: The investigational product (maltodextrin) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: maltodextrin
Description: The investigational product (maltodextrin) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: maltodextrin
Description: The investigational product (maltodextrin) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.
Study: NCT05530902

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Primary Rehabilitation Care
Description: As described by the Policy Regulation 'Innovation' (NZa). The MPRC is a structured treatment program following the biopsychosocial approach, aiming to optimize functioning and participation in CMP patients. The treatment program is provided by paramedical specialists and, in cases that are more complex, a rehabilitation physician will be involved. The program has a diagnostic phase, a treatment phase (6-12 weeks) and a follow-up (12 months).
Study: NCT05963594

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: maltodextrin
Description: The investigational product (maltodextrin) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.
Study: NCT05758298

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-medicated gum
Description: Non-medicated, regular chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NICOTINE 2MG GUM
Description: Nicotine 2mg chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NICOTINE 4MG GUM
Description: Nicotine 4mg chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
Study: NCT05929664

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study: NCT02526303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin Calcium and Warfarin
Description: Warfarin (with nadroparin calcium at the first 5 days at least) until recanalization or 1 year
Study: NCT06267690

Intervention type: PROCEDURE
Intervention: surgery
Description: Patients with suspected pancreatic cancer who underwent contrast-enhanced CT and pathological examinations after the surgery.

Intervention type: PROCEDURE
Intervention: surgery
Description: Patients with suspected pancreatic cancer who underwent contrast-enhanced CT and pathological examinations after the surgery.
Study: NCT05929664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05221255

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: spinal magnetic stimulation
Description: * Biofeedback pelvic floor muscle training sessions will be performed for both groups for a total of 12 sessions. Menstruating women will be temporarily withdrawn from BF sessions till end of the menses. The session will last for 30 minutes of transrectal pressure biofeedback relaxation technique. Auditory and visual feedback will be provided in addition to positive verbal reinforcement.~* Sham SMS will be used in the Sham group using the placebo program in the magnetic stimulation machine.~* Spinal magnetic stimulation using the Neuro-MS/D machine. It will be used in spinal magnetic stimulation group, circular coil will be used to stimulate S2,3 and 4 sacral roots. Intensities will be adjusted to 50-70 % of maximal output (2.2 Tesla), stimulation frequency will be fixed at 20 Hz, burst length = 5 seconds, inter-burst interval = 25 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spinal magnetic stimulation
Description: * Biofeedback pelvic floor muscle training sessions will be performed for both groups for a total of 12 sessions. Menstruating women will be temporarily withdrawn from BF sessions till end of the menses. The session will last for 30 minutes of transrectal pressure biofeedback relaxation technique. Auditory and visual feedback will be provided in addition to positive verbal reinforcement.~* Sham SMS will be used in the Sham group using the placebo program in the magnetic stimulation machine.~* Spinal magnetic stimulation using the Neuro-MS/D machine. It will be used in spinal magnetic stimulation group, circular coil will be used to stimulate S2,3 and 4 sacral roots. Intensities will be adjusted to 50-70 % of maximal output (2.2 Tesla), stimulation frequency will be fixed at 20 Hz, burst length = 5 seconds, inter-burst interval = 25 seconds.
Study: NCT04566757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Plasma
Description: Intravenous Infusion of Umbilical Cord Blood Plasma
Study: NCT06333236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food for Special Medical Purposes: Kron®
Description: Citicoline 40mg/ml + Nicotinamide 15 mg/ml oral solution
Study: NCT04970849

Intervention type: OTHER
Intervention: observation
Description: IBD doctors who perform the endoscopy perform the questionnaire
Study: NCT06238596

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: The rehabilitation intervention will be led by a Physiotherapist and will include: a 12 weeks standardized multicomponent exercise (aerobic, resistance, balance and flexibility, and impact exercise if indicated), supervised by the physiotherapist, on an outpatient basis or in telerehabilitation. This program will be adapted to single patient needs. Every exercise session will last almost 60 minutes and patients will be supervised twice a week. One more exercise session per week will be self-managed by patients.
Study: NCT05168176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotilavir sodium tablet
Description: The subjects randomly received single oral administration of Dotilavir sodium tablet 50mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dotilavir sodium tablet(Tivicay@)
Description: The subjects randomly received single oral administration of Dotilavir sodium tablet 50mg.
Study: NCT06343025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Exercises Group
Description: Individuals will perform clinical pilates exercises for 60 minutes, 3 days a week for 12 weeks. It includes 45 minutes of basic pilates exercises, 10 minutes of warm-up and 5 minutes of cool-down exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi Exercises Group
Description: Individuals will perform Tai Chi exercises for 60 minutes, 3 days a week for 12 weeks. It includes 45 minutes of Tai Chi movements, 10 minutes of warm-up and 5 minutes of cool-down exercises.
Study: NCT05260606

Intervention type: DIAGNOSTIC_TEST
Intervention: F-18 FDG PET/CT
Description: 1. 1st scan: pre-Tx, ICI Tx must be started within 35 days after 1st scan.~2. 2nd scan: interim~   * Pembrolizumab or atezolizumab: after the 2nd Tx cycle to before the start of the 3rd Tx cycle~  * Nivolumab: after the 3rd Tx cycle to before the start of the 4th Tx cycle~3. 3rd scan: optional (3rd scan can be performed when disease progression is suspected)~4. Imaging~   * Fasting: at least 6 hours~  * Blood glucose level: \< 200 mg/dL~  * F-18 FDG 0.14 mCi/kg (IV)~  * Image acquisition: 1 hr after FDG injection, CT images are acquired. After CT scan, PET images are acquired and attenuation-corrected PET images are reconstructed based on the CT image data.~  * PET/CT: Discovery MIDR or MI (GE Healthcare, Chicago, Illinois, USA)~  * First and second scans have to be performed with same scan.
Study: NCT05184127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIR 19 ®
Description: Drug contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Standard COVID-19 therapy
Description: Therapy carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection. This therapy included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b. In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard COVID-19 therapy
Description: Therapy carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection. This therapy included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b. In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b
Study: NCT05190536

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ho:YAG lasers
Description: Under the guidance of B-ultrasound or X-ray, the appropriate target calyx was punctured with an 18G puncture needle.Percutaneous tract was established with 18Fr suction sheath. 12Fr nephroscope and 360um Ho:YAG laser fiber was used for lithotripsy.Kidney stones were fragmented by Ho:YAG lasers, and sucked out by the suction sheath.
Study: NCT05656521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 101-PGC-005
Description: '005 is a targeted prodrug of dexamethasone that binds to activated macrophages.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone is a glucocorticoid commonly prescribed to treat inflammation.
Study: NCT05364060

Intervention type: OTHER
Intervention: Questionnaires
Description: Different questionnaires detailed in the objectives part
Study: NCT05476419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct intra-oral scanning technique for the post space.
Description: scanning of prepared dental post space directly inside the patient mouth by using an intra-oral scanner

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Direct intra-oral scanning technique for the post space.
Description: scanning of prepared dental post space directly inside the patient mouth by using an intra-oral scanner
Study: NCT05190536

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TFL
Description: Under the guidance of B-ultrasound or X-ray, the appropriate target calyx was punctured with an 18G puncture needle.Percutaneous tract was established with 18Fr suction sheath. 12Fr nephroscope and 360um TFL fiber was used for lithotripsy.Kidney stones were fragmented by TFL, and sucked out by the suction sheath.
Study: NCT05929664

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study: NCT05839639

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NrtIs
Description: Subjects will receive NrtIs therapy for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH-003
Description: Subjects will receive HH-003 20 mg/kg intravenously Q2W for 24 weeks.
Study: NCT06341595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab: 200mg iv q3w d1, 4-6 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Extraperitoneal radiation therapy
Description: Radiotherapy using extraperitoneal radiation therapy, once a day, 5 times a week, 1.8-2 Gy/f, a total of 45-50.4 Gy (lymph node lesion radiation dose of 60-66 Gy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: oxaliplatin: 130mg/m\^2, D1, Q3W, 4-6 cycles
Study: NCT05839639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH-003+NrtIs
Description: Subjects will receive HH-003 20 mg/kg intravenously Q2W for 24 weeks. Subjects will receive NrtIs therapy for 24 weeks.
Study: NCT05985070

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Ferric pyrophosphate
Description: 30 mg capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Sodium ferric pyrophosphate
Description: 30 mg capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Ferric maltose
Description: 30 mg Tablet
Study: NCT06341595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1: 40mg/m\^2, bid, d1-14, 4-6 cycles
Study: NCT06138808

Intervention type: OTHER
Intervention: Stereoelectroencephalography (SEEG)
Description: Participants will under Stereoelectroencephalography (SEEG) as part of standard of care. This is not assigned by the protocol.
Study: NCT04601974

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: lentiviral gene therapy
Description: lentiviral gene therapy to treat drug resistant epilepsy
Study: NCT06056128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic assisted bronchoscopy
Description: Robotic assisted bronchoscopy of peripheral airways for the purpose of biopsying lung lesions
Study: NCT06174155

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy treatment
Description: The control group will receive the physical therapy program and conduct five times per week over four consecutive weeks under the supervision of a physical rehabilitation specialist. The primary focus of the program was to improve scar malleability, lengthen muscles and tendons, enhance joint mobility, and to restore functionality. Each session lasted almost for 45 minutes and consisted of therapeutic paraffin application; deep tissue massaging (5 minutes); stretching exercises; active ROM exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin-A injection in addition to physical therapy program
Description: Two injection procedures will be used. The first is an EMG-guided BTX-A administration (Botox®, Allergan PLC, Dublin, Ireland) that will be localized to the motor endplate zone of the wrist flexors, radial and ulnar deviators. The second is a meso-injection procedure, where the BTX-A will be injected subdermal, intradermal, and into the scar (around the periphery and into the center).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: shock wave therapy in addition to physical therapy program
Description: After wound and skin graft healing (\~ 90 days post-surgery), the unfocused shockwave will be applied to the site of burn injury on the volar aspect of the hand of the subjects and will allocate to the shock wave therapy intervention arm. The treatment will be delivered using a portable shockwave device (Zimmer enPuls, EMS physio Ltd, Germany).
Study: NCT06406244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS group
Description: Transcutaneous electrical acupoint stimulation (TEAS) is a contemporary modification of traditional acupuncture that sends electrical impulses into acupoints through electrodes on the skin surface. In the TEAS group, patients will receive TEAS 30 min before anesthesia until be discharged from the post-anaesthesia care unit (PACU). The same treatment will be performed on the 1st, 2nd and 3rd days after surgery. The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham group
Description: Patients in the sham group will receive electrode attachment but without stimulation.
Study: NCT05393999

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986414
Description: Broadly neutralising antibodies BMS-986414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986413
Description: Broadly neutralising antibodies BMS-986413
Study: NCT05163327

Intervention type: PROCEDURE
Intervention: Oxygen-enhanced Cardiac MRI
Description: The MRI scan will include assessment of cardiac function. Myocardial magnetic properties (T1, T2, T2\*) will be measured while patients are breathing room air, oxygen and during an infusion of adenosine. The scan will last for approximately 60 minutes. Prior to the scan patients will have an intravenous cannula (venflon) placed in an arm vein.

Intervention type: PROCEDURE
Intervention: Oxygen-enhanced Cardiac MRI
Description: The MRI scan will include assessment of cardiac function. Myocardial magnetic properties (T1, T2, T2\*) will be measured while patients are breathing room air, oxygen and during an infusion of adenosine. The scan will last for approximately 60 minutes. Prior to the scan patients will have an intravenous cannula (venflon) placed in an arm vein.
Study: NCT06397859

Intervention type: DRUG
Intervention: Bulevirtide
Description: dose of 2 mg/day subcutaneously
Study: NCT04926844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Intravenous levetiracetam 60 mg/kg (max 4500 mg) over 5 minutes (diluted with isotonic saline to a concentration of 50 mg/ml).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous isotonic saline (1.2 ml/kg) over 5 minutes
Study: NCT04901806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-200
Description: PBI-200 will be administered orally over continuous 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-200
Description: PBI-200 will be administered orally over continuous 28-day cycles
Study: NCT05895123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Description: patients will receive one tablet rosuvastatin 20 mg every night

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg
Description: patients will receive one tablet Atorvastatin 40 mg every night